#Sweden #Milan #Sobi #EHA 2025 #hematologic diseases

Sobi to Present New Insights on Hematologic Diseases at EHA 2025

Sobi® (STO: SOBI), a global biopharmaceutical leader, is set to unveil its latest clinical findings at the upcoming 30th European Haematology Association (EHA) congress, scheduled to take place from June 12 to 15, 2025, in Milan, Italy. This esteemed hybrid congress will focus on innovative treatment strategies for various hematologic conditions, including diffuse large B-cell lymphoma (DLBCL), immune thrombocytopenia (ITP), myelofibrosis, paroxysmal nocturnal hemoglobinuria (PNH), and primary hemophagocytic lymphohistiocytosis (pHLH).

Commitment to Rare Diseases

Sobi’s participation underscores its unwavering commitment to advancing therapies for rare diseases. An extensive program of poster presentations will illuminate the company's significant contributions to enhancing treatment options for patients suffering from these intricate hematologic disorders. Alongside these presentations, Sobi will host nine scientific symposiums addressing pertinent topics that aim to reshape disease management and therapeutic approaches in the field.

Key Symposiums

1. Advancing Therapeutic Knowledge in Paroxysmal Nocturnal Hemoglobinuria
Date & Time: Thursday, June 12, 10:00 AM - 11:30 AM CEST
Location: Amber Hall 3 & 4
- This session will explore innovative strategies to improve outcomes in patients with PNH.

2. Boosting Platelets: Expert Approaches to Adult Immune Thrombocytopenia (ITP)
Date & Time: Saturday, June 14, 8:00 AM - 9:30 AM CEST
Location: Amber Hall 7 & 8
- Here, experts will share advances and clinical experiences related to ITP therapy.

3. Dissecting Treatment Sequencing in Relapsed/Refractory DLBCL
Date & Time: Saturday, June 14, 8:00 AM - 9:30 AM CEST
Location: Coral Hall 1
- This discussion will cover treatment regimens and their real-world implications based on recent data.

Significant Data Presentations

Sobi will present critical data at EHA 2025 that demonstrates its detailed approach to tackling rare hematological conditions. Highlights include:

• - DLBCL

- New insights from the LOTIS-7 Phase 1b study on the combination of Loncastuximab Tesirine and Glofitamab for patients with relapsed or refractory DLBCL.

• - Immune Thrombocytopenia (ITP)

- Findings from the REAL-AVA 2.0 Real-World Study examining the impact of Avatrombopag, focusing on durability and safety across various patient profiles.

• - Myelofibrosis

- Evaluating effectiveness and safety from PACRITINIB in treating myelofibrosis, showcasing real-world clinical outcomes.

Innovation in Rare Disease Treatments

One of the standout innovations that Sobi aims to highlight is Pegcetacoplan, a targeted therapy for controlling excessive complement activation—often linked with severe complications in patients with PNH and other rare diseases. Its efficacy is already recognized in multiple regions.

Doptelet® (avatrombopag) is also a notable mention, specifically approved for treating chronic immune thrombocytopenia in patients who do not respond well to other medications. Furthermore, Zynlonta® (loncastuximab tesirine) has gained acknowledgment for its role in treating adult patients with relapsed or refractory DLBCL after multiple lines of prior therapy.

Conclusion

Sobi's participation in EHA 2025 represents a significant stride in its ongoing journey to support patients with rare hematologic conditions through research and innovative therapies. As the congress approaches, professionals from various sectors will engage in fruitful discussions aimed at improving patient outcomes worldwide.

About Sobi
Sobi is a biopharmaceutical company dedicated to unlocking solutions for people affected by rare diseases. With a global team of approximately 1,900 employees, the company emphasizes transformative research to enhance lives. In 2024, Sobi reported a revenue of SEK 26 billion, emphasizing its growth and commitment to the healthcare community. For further details about Sobi and its initiatives, visit sobi.com.